CMN LIFU for Enhanced Glymphatic Clearance in Amyloid-Positive MCI
NCT07866768
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to learn if a wearable ultrasound device, called ATTN201, is safe and easy to use. The study is for adults ages 65 and older who have mild cognitive impairment (MCI) and a buildup of a protein called amyloid in the brain. Amyloid buildup is an early sign of Alzheimer's disease. The ATTN201 device sends low-intensity sound waves to a deep area of the brain that helps control sleep. The aim is to boost deep-sleep brain waves. These brain waves may help the brain clear away waste, including amyloid.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alzheimer's Disease (AD)
- Mild Cognitive Impairment (MCI)
- Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of California, San Francisco
- Last updated on ClinicalTrials.gov
- October 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California San Francisco · San Francisco, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.